# Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Source: https://onco.cc/trials/nct07154706/  
OnCo record `nct07154706` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Taletrectinib in non-small-cell lung cancer and small-cell lung cancer, run by Nuvation Bio Inc., now recruiting.

## Summary

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) is a phase 3 interventional study registered as NCT07154706 by Nuvation Bio Inc., with 180 participants planned, started 2025-08-21 and due to reach its primary completion in 2030-08-30. Interventions recorded: Taletrectinib, Placebo. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07154706
- Phase: 3
- Setting: A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection
- Sponsor: Nuvation Bio Inc.
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT07154706: https://clinicaltrials.gov/study/NCT07154706

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Taletrectinib](https://onco.cc/drugs/taletrectinib/)
- companies: [Nuvation Bio](https://onco.cc/companies/nuvation-bio/)

---
JSON: https://onco.cc/api/v1/entities/nct07154706.json